Misplaced Pages

Neuronal Alpha-Synuclein Disease

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by A455bcd9 (talk | contribs) at 20:09, 26 December 2024. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 20:09, 26 December 2024 by A455bcd9 (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Neuronal Alpha-Synuclein Disease is a proposed new combined definition of Parkinson's disease and Lewy Body dementia based on biology instead of symptomatology.

  1. "Major Shift in the Clinical Definition of PD Triggers Debate". Medscape. Retrieved 2024-12-26.
  2. "New Parkinson's Definition Proposed Based on Biomarkers". January 26, 2024.
  3. Simuni, Tanya; Chahine, Lana M; Poston, Kathleen; Brumm, Michael; Buracchio, Teresa; Campbell, Michelle; Chowdhury, Sohini; Coffey, Christopher; Concha-Marambio, Luis; Dam, Tien; DiBiaso, Peter; Foroud, Tatiana; Frasier, Mark; Gochanour, Caroline; Jennings, Danna (2024-02-01). "A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research". The Lancet Neurology. 23 (2): 178–190. doi:10.1016/S1474-4422(23)00405-2. ISSN 1474-4422. Archived from the original on 2024-02-01.
  4. Pagano, Gennaro; Dam, Tien; Kerchner, Geoffrey A.; Galpern, Wendy R.; Biagioni, Milton; Karan, Rajesh; Jennings, Danna; Peterschmitt, M. Judith; Nikolcheva, Tania; Brundin, Patrik (2024-12-20). "Biologically defined neuronal synuclein disease as a tool to advance drug development". npj Parkinson's Disease. 10 (1): 1–3. doi:10.1038/s41531-024-00845-5. ISSN 2373-8057.